Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

Clinical trial NCT06410651 · RECRUITING

Trial details

NCT number: NCT06410651
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Cancer Nimotuzumab Chemoradiotherapy Chemotherapy Immunotherapy

Start date: 2023-03-01
Primary completion: 2025-12-31
Enrollment: 53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.